. 2014 Feb;58(2):672–677. doi: 10.1128/AAC.01516-13

TABLE 3.

Mean observed change in log₁₀ CFU for each treatment regimen against each isolate

Regimen	Δ (log₁₀ CFU at 96 h)^a			Mean Δ (log₁₀ CFU at 96 h)^b
Regimen	MRSA	hVISA	VISA	Mean Δ (log₁₀ CFU at 96 h)^b
Vancomycin	−3.15 ± 0.6	−1.57 ± 1.0	0.52 ± 0.3	−1.40 ± 1.8
Ceftaroline	−4.12 ± 1.1	−3.65 ± 0.1	−3.03 ± 0.5	−3.60 ± 0.6
Daptomycin	−3.12 ± 0.6	−2.51 ± 1.1	−1.10 ± 0.1	−2.24 ± 1.0
Vancomycin, ceftaroline	−5.98 ± 1.2	−3.82 ± 0.6	−5.87 ± 1.0	−5.22 ± 1.2
Vancomycin, daptomycin	−2.35 ± 0.2	−1.24 ± 0.0	−0.36 ± 0.3	−1.32 ± 1.0

Data presented are the mean ± standard deviation of two models during each experiment.

Using data from all isolates, the sequential treatment regimen of vancomycin followed by ceftaroline achieved statically greater reductions in 96-h CFU than single-drug therapy with ceftaroline (P = 0.010), single-drug therapy with ceftaroline achieved significantly greater reductions in 96-h CFU than single-drug therapy with daptomycin (P = 0.037), and all other regimens achieved CFU reductions that were statistically similar to those of single-drug therapy with daptomycin (P > 0.05).